Tissue transglutaminase (TG) is an enzyme that stabilizes the structure of tissues by covalently ligating extracellular matrix molecules. Expression and localization of TG are not well established during wound healing. We performed punch biopsy wounds on anesthetized rats and monitored the wound healing process by histological and immunohistochemical methods. The TG antigen and activity are expressed at sites of neovascularization in the provisional fibrin matrix within 24 h of wounding. Endothelial cells, macrophages, and skeletal muscle cells expressed TG throughout the healing process. The TG antigen within the wound was active in vivo based on the detection of isopeptide bonds. The TG antigen increased four-to fivefold by day 3 postwounding and was proteolytically degraded. TG expression occurred in association with TGF-␤, TNF-␣, IL-6, and VEGF production in the wound. Recombinant TG increased vessel length density (a measure of angiogenesis) when applied topically in rat dorsal skin flap window chambers. We have established that TG is an important tissue stabilizing enzyme that is active during wound healing and can function to promote angiogenesis.-Haroon, Z. A., Hettasch, J. M., Lai, T.-S., Dewhirst, M. W., Greenberg, C. S. Tissue transglutaminase is expressed, active, and directly involved in rat dermal wound healing and angiogenesis. FASEB J. 13, 1787-1795 (1999) 
Wound healing is a complex and intricate process initiated in response to injury that restores the function and integrity of damaged tissues. Wound healing involves continuous cell-cell and cell-matrix interactions that allow the process to proceed in overlapping stages, i.e., inflammation, proliferation, and remodeling (1) . Defects in any phase of wound healing can contribute to the pathology of many diseases (psoriasis, rheumatoid arthritis, etc.) and tumor growth (2) . The tissue transglutaminase (TG) 2 is a calcium-dependent enzyme that covalently cross-links a wide variety of extracellular matrix (ECM) proteins, producing a protease-resistant matrix, and is reported to be expressed at sites of inflammation (3) . The TG therefore appears to play a role in tissue repair and seems to be involved in several phases of wound healing.
The TG catalyzes the formation of ε-(␥-glutamyl) lysine bonds (isopeptide bond) between peptidebound glutamine residues and the primary amine group of various amines (4) . These isopeptide bonds are stable and more resistant to proteolytic degradation than noncovalent linkages. The covalent crosslinking reaction increases the resistance of proteins to chemical, enzymatic, and physical disruption (3) . The list of proteins that are TG substrates is extensive and includes extracellular adhesive proteins such as fibronectin (5) , collagen (6) , fibrinogen (7), fibrin (8) , laminin/nidogen (9), osteopontin (10) , and vitronectin (11) , to name a few. Recent data have implicated TG in several intra-and extracellular processes that are critical for wound healing including apoptosis (12) , osteogenesis (13) , cellular signaling (14) , and cell adhesion (15) .
Bowness et al. (16, 17) reported TG activity was present at sites of wound healing and that inhibition of TG by putrescine caused decreased breaking strength and increased solubility of the repairing wound tissue (18) . However, the cellular expression, distribution, and metabolic fate of the TG at sites of wound healing in relationship to the expression of cytokines and migration of inflammatory cells were not investigated. The goal of this study was to identify the distribution of TG antigen, its activity, and the metabolic fate of TG during wound healing. In addition, the expression of various cytokines and inflammatory cells associated with the expression of TG was analyzed. Last, a direct effect of TG on angiogenesis was studied in an in vivo window chamber model. These studies and their implications add direct significance to the role of TG in wound healing and angiogenesis.
MATERIALS AND METHODS

Animal protocols
The Duke Institutional Animal Care and Use Committee approved all animal protocols.
Wounds
Fisher 344 female rats from Charles River Laboratories (Raleigh, N.C.) were anesthetized with intraperitoneal injections of pentobarbital (40 mg/kg) and ketamine (70 mg/kg), then shaved and depilated using Nair (Carter-Wallace, New York, N.Y.). Eighteen 5 mm biopsy punch wounds were made on the dorsal skin. The normal skin served as unwounded skin controls. Wounds were harvested at days 1 through 9 while animals were anesthetized. Days 0, 1, 3, 5, 7, and 9 postwounding were used in Western blots; days 0, 1, 2, 4, 6, and 8 were used for immunohistochemistry. Two rats were killed for each time point by intravenous pentobarbital overdose and the experiments were done in triplicate. Tissues were either snap-frozen in liquid nitrogen for Western blots and kept at Ϫ80°C or fixed in 10% neutral buffered formalin for paraffin embedding for immunohistochemistry.
Window chambers
Dorsal skin flap window chambers were used as described by Papenfuss et al. (19) . Briefly, Fisher 344 rats were anesthetized and the skin over the back was depilated and surgically prepared. The skin flap was pulled dorsally away from the back. Two opposing 1 cm diameter windows were created on each side of the flap by surgically resecting the epidermis. One to two fascial planes were left, which contained a few preformed vessels. The resultant subcutaneous (s.c.) window was protected by glass coverslips and held away from the body of the animal by an anodized aluminum superstructure. This wounded tissue window created a visual field through which the process of wound healing could be observed noninvasively. Recombinant human TG (500 l of 40 g/ml or 40 M) (20) was applied topically on the day of surgery and on days 1 and 2 postsurgery. Normal saline was used as a control. Rats were killed at day 10. Intravital microscopy was used to document the level of neovascularization at days 1 and 10. Quantitation of angiogenesis was provided by measuring vessel length density (21) .
Immunohistochemistry
Immunohistochemistry was carried out using procedures described by Hsu et al. (22) . Briefly, paraffin embedded tissues were sectioned (5 ) and antigen retrieval was performed using citrate buffer from Biogenex (San Ramon, Calif.). Tissues were treated with primary antibody against tissue transglutaminase (TG100 and CUB 7402, 1:10, nonreactive to factor XIIIa: both monoclonals were epitope mapped to a region between 447-538 amino acids; unpublished results), vascular endothelial growth factor (VEGF 3; 1:100; Neomarkers, Fremont, Calif.), ED1-macrophage marker (MCA341, 1:100; Serotec, Oxford, U.K.), isopeptide (814 MAM, 1:75; CovalAB, Oullins, France) (23, 24) , panspecific tumor growth factor ␤ (TGF-␤: AB-100-NA, 1:100, which recognizes the active forms of TGF-␤1, 2, and 5), rat antitumor necrosis factor ␣ (anti-TNF-␣: AB-510-NA, 1:100; R&D, Minneapolis, Minn.), interleukin 6 (R-19, 1:100; Santa Cruz, Santa Cruz, Calif.), and mast cell tryptase (M7052, 1:100; DAKO, Carpinteria, Calif.). Secondary and tertiary antibodies were provided in a kit (314KLD) by Innovex (Richmond, Calif.) and the location of the reaction was visualized with 3, 3Ј-diaminobenzidine tetrahydrochloride Sigma (St. Louis, Mo.). Slides were counterstained with hematoxylin and mounted with coverslips. Controls for the immunohistochemistry were treated with normal mouse serum (NMUS) or mouse immunoglobulin G (IgG) (TG100, CUB 7402, 814 MAM, M7052, VEGF 3, and MCA 341), rabbit IgG (AB-100-NA), and goat IgG (IL-6, AB-510-NA) and were negative in any reactivity. Masson's trichrome and hematoxylin and eosin were carried out as described by Sheehan and Hrapchak (25) .
Western blot
Wounds from days 0, 1, 3, 5, 7, and 9 were homogenized in 2 ml cold lysis buffer containing the proteolytic inhibitor mixture (#1697498; Boehringer Mannheim, Mannheim, Germany), followed by sonification. The blots were performed with four different wound sets. They were then centrifuged, and supernatant was removed and protein content was determined using Bio-Rad. Gel electrophoresis of the extracted tissue samples (50 g/ml) was performed on an 8.5% polyacrylamide gel using the buffer system of Laemmeli. After electrophoresis, the proteins were transferred to nitrocellulose (0.2 M). When the transfer was complete, the nitrocellulose membrane was blocked for 1 h with 5% nonfat milk dissolved in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.5% Tween 20. The TG antigen was detected by incubation for 1 h using a monoclonal antibody for TG (TG 100, CUB 7402; Neomarkers) diluted 1:1000, followed by incubation for 1 h with sheep antimouse IgG conjugated to horseradish peroxidase. The TG antigen was visualized using chemiluminescence reagents (ECL, Amersham, Arlington Heights, Ill.) and a 30 s exposure to autoradiography film. The amount of protein on the blot was estimated with a densitometer. The data in Fig. 5A show one sample blot, and Fig. 5B contains the cumulative data for the four blots in a graphical presentation.
RESULTS
Light microscopy findings
At the earliest time point at day 1 (Fig. 1A) , provisional matrix with inflammatory cells ( Fig. 2A) and dilated blood vessels could be observed underneath a newly formed epithelial layer. Re-epithelialization was completed by day 2 postwounding. Maturation of granulation tissue was detected by day 4 (Fig. 1B) and characterized by the presence of new blood vessels, inflammatory cells (Fig. 2B, C) , and collagen fibers organized into a dense connective tissue. Skel-etal muscle cells that had formed a boundary between the normal and wounded tissue at earlier time points now moved to the base of the wound and closed the gap created by the injury (Fig. 1B) . By day 6 ( Fig. 1C) , granulation tissue started to contract and increased in density. At day 8 ( Fig. 1D ) the healing was in its final stages, with remnants of granulation tissue left at the base of the wound. The injury site was filled with dense collagen tissue, with very few blood vessels. The widely recognized three stages of wound healing (1) and their time course in our model of healing are depicted at the bottom of Fig. 1 .
Expression and localization of TG
The normal rat skin consistently expressed TG antigen in the blood vessels that reside in the dermis and s.c. tissue (Fig. 3A) . Some sebaceous glands and basal keratinocytes also showed expression, but in a sporadic fashion. The TG antigen was detected in the new blood vessels, which invaded the provisional fibrin matrix and the dilated blood vessels at day 1 postinjury (Fig.  3B-D) . The TG antigen staining was particularly intense in macrophages adjacent to the re-epithelialization border and in the provisional matrix (Fig. 3B, C) . Mast cells (Fig. 2D) were present in highest density on day 1 postwounding and exhibited TG expression. The keratinocytes involved in re-epithelialization expressed TG antigen (Fig.  3B) . TG reactive skeletal muscle cells, macrophages, and blood vessels formed a distinct boundary between the normal and injured tissue (Fig.  3C) . TG was also detected in the provisional fibrin matrix (Fig. 3D) . By day 2, re-epithelialization was complete and TG expression was reduced in the epithelial layer and limited to the dermoepidermal junction. The provisional fibrin matrix was slowly replaced by granulation tissue by day 2, and the wound began to accumulate collagen and TG antigen reactivity. TG immunoreactivity in the collagen also increased as the number of endothelial cells, macrophages, and skeletal muscle cells increased in the wound.
The TG antigen (Fig. 3E) and macrophage ( Fig.   2B ) staining was absent from the keratinocyte layer at day 4. Macrophages, endothelial cells in the neovessels, and more mature vessels continued to stain for the TG antigen (Fig. 3E) . The TG reactive skeletal muscle cells started to move underneath the wounded tissue to bridge the gap created by injury (Fig. 3E) . TG was still present in the granulation tissue matrix at day 4 (Fig. 3F) . As the granulation tissue continued to contract and the tissue was further remodeled (day 6), the highly reactive TG at the edge of the wound vanished and TG staining became localized to the blood vessels and base of the wound (Fig. 3G) . By day 8, the early granulation tissue was replaced with a dense collagen-rich scar. The TG antigen was predominantly expressed in blood vessels, skeletal muscles, and macrophages at the base of the wound (Fig. 3H) . A few remaining vessels in the scar tissue also exhibited TG staining (Fig. 3H) .
Localization of TG activity
The isopeptide bond created by TG cross-linking was detected surrounding blood vessels, newly generating epithelial layer, and fibrin by day 1 of wounding (Fig. 3I) . The intensity of immunoreactivity of the isopeptide bond increased within the ECM of the granulation tissue, basement membrane of blood vessels, and along the epithelial region at day 4 ( Fig. 3J) . In contrast to the reduction of staining for TG and the redistribution of the TG antigen to the base of the wound, the isopeptide bond antigen continued to be detectable, but at a reduced level, during the formation of the dense scar tissue at day 8.
Expression of cytokines (TGF-␤, TNF-␣, IL-6, and VEGF)
TGF-␤ was maximally expressed at the wound surface, granulation tissue, and wound border over the entire time course examined (Fig. 4A) . The intensity of staining was greatest in regions where TG antigen reactivity was the highest. The one exception to this finding was in the mature epithelial layer at day 4, where TGF-␤ antigen was expressed but TG was absent.
Interleukin 6 (IL-6) stained intensely in the skeletal muscle cells of the dermis throughout the study (Fig. 4B) , with less intense staining in the macrophages, fibroblasts, and endothelial cells during the early wound healing (days 1-4). IL-6 coexpressed with TG in the skeletal muscle cells at all time points examined. TNF-␣ stained predominantly macrophages in the wounded tissue and coexpressed with TG in those cells throughout the healing process (Fig. 4C) . Endothelial cells and skeletal muscle cells also exhibited partial expression of this cytokine.
The endothelial cells and macrophages expressed VEGF antigen at day 1 postwounding (Fig. 4D ), which correlated with TG expression. VEGF expression in endothelial cells and macrophages decreased in intensity even though TG continued to be expressed at high levels at day 4. By day 8, TG and VEGF coexpressed in remnant blood vessels in the scar tissue.
A summary of the immunohistochemical data is provided in Table 1 .
Western blot analysis of TG antigen in wounded tissue
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and quantitative immunoblotting demonstrated that the total TG antigen increased from four-to fivefold by day 3 (Fig. 5A, B) . Quantitative analysis of the antigen (nϭ4) revealed that more than 95% of the protein was proteolytically degraded to 55, 50, and 20 kDa fragments by day 1 postwounding. The extent of proteolysis and the amount of TG antigen reached maximum by day 3, after which the full-length TG antigen was detected. The total TG antigen levels returned to baseline values by day 9. However, the amount of intact protein was still considerably reduced compared with the control skin tissue. 
Effect of recombinant TG on angiogenic response in rat dorsal skin flap chamber
To determine what effect the active TG had on dermal wound healing, we used the rat dorsal skin flap window chamber to administer full-length recombinant TG and measure its effects on angiogenesis. When recombinant TG was applied to fascia in the rat dorsal skin flap window chambers, a significant doubling in the vessel length density was measured at day 10 compared to controls (Pϭ0.05) (Fig. 6) .
DISCUSSION
The potential roles that TG plays during various stages of wound healing are summarized in Fig. 7 . The TG could be exerting its effects during wound healing either in 1) response to injury cytokines, 2) stabilization of provisional fibrin matrix, 3) migration of endothelial and inflammatory cells, and/or 4) remodeling of the granulation tissue through apoptosis and cross-linking.
The finding that both TG expression and activity were increased very early during wound healing demonstrated that the TG gene was activated in cells that were migrating into the fibrin clot and/or remodeling the ECM. The TG gene has regulatory elements that appear to be responsive to acute-phase injury cytokines including TGF-␤ (26), IL-6 (27), and TNF-␣ (28). TG's ability to be induced by TGF-␤ (26), IL-6 (27), and TNF-␣ (28) and its association with expression of these cytokines and VEGF during wound healing indicated a pivotal role during this process. These cytokines are essential in orchestrating a defined sequence of events to complete the healing process. TG's association with these cytokines during wound healing illustrates that the TG gene could be induced by these cytokines and function to aid in tissue repair. These findings also indicate that complicated and dynamic interactions exist between the cytokines and TG.
There is an important interaction between TGF-␤ Quantitative analysis of Western blots (nϭ4). Plot shows TG and its fragments at days 0 through 9, taking total TG at day 0 (normal skin) as 100%. Total TG increases 4 to 5 times on day 1 and 3 and slowly falls to basal level by day 9. Full-length TG constitutes more than 80% of total TG at day 9, but is reduced to less than 5% by day 1 and recovers to only ϳ25% at day 9. The 55, 50, and 20 kDa form a minimal portion of total TG at day 0. The amount of fragmented TG increases dramatically by day 1; 55 and 50 kDa forms account for as much as 40% each of total TG. All fragments start to decline by day 5 and make up only ϳ25% each at day 9 of total TG.
and TG that could amplify production of granulation tissue. TG is bound to cell surface complexes comprised of plasminogen, uPAR, and the mannose-6-phosphate receptor (29) . The function of this complex is to facilitate the conversion of latent TGF-␤ to its active form (29) . Our immunohistochemistry results show maximal staining for active TGF-␤ in areas demonstrating high TG immunoreactivity when the provisional fibrin matrix is being replaced by newly synthesized connective tissue. This interaction appears to be operational in the second phase of wound healing. The increased activation of TGF-␤ by TG could lead to the expression of TG gene early within the fibrin clot and at sites of re-epithelialization, since the TG gene itself is induced by TGF-␤. TG and TGF-␤ effectively complete a positive amplification loop whereby the TG increases TGF-␤ activation, which then induces more TGF-␤ activity to further amplify TGF-␤ activation and TG expression (Fig. 7) . The end product of this process is the replacement of fibrin matrix with granulation tissue. The early expression of TG by endothelial cells and macrophages invading the fibrin clot observed during wound healing appeared to stabilize the fibrin, since isopeptide bonds were detected in both the fibrin and the newly synthesized loose granulation tissue. Isopeptide bonds could be generated by other isoforms of TG, including factor XIIIa and epidermal transglutaminase. We cannot quantitate to what extent factor XIIIa or TG is responsible for the generation of isopeptide bonds. However, the distribution of factor XIIIa in wounds is different from that of TG antigen reported in this study (30) . Earlier studies of patients with factor XIIIa deficiency have shown wound healing defects in only 20% (31) , suggesting an alternate pathway of fibrin stabilization in the tissues of these patients. Factor XIIIa requires thrombin for activation while TG is synthesized in an active form (32) . The factor XIIIa molecule may be responsible for the isopeptide bonds formed within the fibrin clot. Since TG does not require thrombin activation, it can catalyze the stabilization of newly formed ECM as thrombin is removed from the wounded tissue. The TG in human blood vessels catalyzes the ␣-␣ cross-links of fibrin and fibrinogen in human atherosclerotic plaques (33) , demonstrating that this enzyme is active during human disease process. The stabilization of the matrix by TG could regulate assembly of the granulation tissue and the neovascularization that is essential for an effective healing response.
The transient expression of TG in the epithelial layer suggested a role of TG in re-epithelialization and keratinization, as reported by others. Raghunath et al. (34) found that TG was expressed at the dermoepidermal junction in wounds. They sug- gested that TG might play a role in attaching the epithelial layer to the dermoepidermal junction. TG might be responsible for the earlier re-epithelialization episode, and epidermal transglutaminase takes over later to stabilize the mature epithelial layer as TG expression diminishes. Deficiency of epidermal transglutaminase results in ichthyosis, not a total breakdown of the skin barrier, which suggests there are other transglutaminases that can maintain epidermal integrity (35) .
TG could promote wound contraction by crosslinking ECM molecules at the edge of the wound. Cohen et al. (36) suggested that the plasma factor XIII transglutaminases expressed by platelets contributed to the contraction of the fibrin clot. By ligating protein molecules throughout the wound, the TG could lead to more effective wound contraction. The TG expression by skeletal muscle cells and location of TG activity at these sites could also firmly anchor granulation tissue with the existing tissues to promote wound closure.
Migration of endothelial and inflammatory cells into fibrin forms an indispensable part of the healing process. Major proinflammatory and angiogenic cytokines such as TGF-␤, TNF-␣, and VEGF exert their influence by promoting migration of cells to the injured site, and the scaffolding function of fibrin has been shown to be an essential part of VEGFmediated migration of endothelial cells (37) . During migration, the stability of the provisional fibrin matrix is of utmost importance and TG's ability to stabilize the matrix that resists degradation may be vital for orchestrating tissue repair.
Adding recombinant TG to the sites of skin wound healing caused an increase in the vessel length density, a measure of neovascularization in the rat skin. The TG could be an important mediator of angiogenesis by regulating important events in vascular assembly either directly by its covalent modification of proteins or indirectly by modifying TGF-␤ function. TGF-␤ function is essential for normal vascular development (38) , since defects in the TGF-␤ binding protein endoglin lead to the congenital vascular malformation syndrome of hereditary hemorrhagic telangiectasia (39) . In ongoing experiments we have found that TG placed in a fibrin chamber enhances angiogenesis (unpublished results). Additional studies are in progress to define the mechanisms responsible for TG-mediated enhancement of angiogenesis in fibrin.
The proteolytic degradation of the TG may provide a method to regulate the duration and extent of the cross-link reaction. By degrading the TG, the positive amplification loop between TG expression and TGF-␤ activation would be disrupted and allow tissue remodeling to occur in the granulation tissue. Extracts from the wound could degrade recombinant TG, which demonstrated that there was proteolytic processing of the TG (unpublished results).
In conclusion, we have established that TG antigen and activity are expressed and function within the wound at sites of neovascularization and granulation tissue formation. TG appears to undergo regulation with the cytokines and directly promote angiogenesis.
